Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BPL plasma products: new source, enhanced products.

D S Kumararatne1

  • 1Regional Immunology Department, Birmingham Heartlands Hospital.

Hospital Medicine (London, England : 1998)
|March 4, 2000
PubMed
Summary

Bio Products Laboratory is transitioning plasma sources from the UK to the USA. This ensures continued supply of plasma-derived medicines through rigorous plant cleaning and regulatory audits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017.

Clinical and experimental immunology·2018
Same author

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

The Journal of allergy and clinical immunology·2016
Same author

Cytolytic activity against mycobacterial antigens: differences between haemophiliacs with and without HIV infection.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Familial hepatopulmonary syndrome in common variable immunodeficiency.

Journal of clinical immunology·2015
Same author

The lymphocytes of splenic marginal zones: a distinct B-cell lineage.

Immunology today·2014
Same author

Another look at chronic lymphocytic leukaemia in the context of B-cell differentiation.

Immunology today·2014

Area of Science:

  • Biotechnology
  • Pharmaceutical Manufacturing
  • Plasma Fractionation

Background:

  • Bio Products Laboratory (BPL) is a primary fractionator of plasma-derived medicinal products.
  • A critical transition is underway, shifting from UK-sourced plasma to USA-sourced plasma.
  • This change necessitates careful management to ensure product safety and supply continuity.

Purpose of the Study:

  • To detail the process of transitioning plasma sourcing for medicinal product manufacturing.
  • To outline the strategies employed by BPL to maintain supply chain integrity during this change.
  • To highlight the importance of regulatory compliance and plant hygiene in managing source material changes.

Main Methods:

  • Implementation of meticulous cleaning protocols for the production plant.
  • Undergoing extensive auditing by internal teams and external regulatory authorities.
  • Phased transition of plasma sourcing from UK to USA.

Main Results:

  • The transition process is being managed to ensure continuity of supply for essential medicines.
  • Rigorous cleaning and auditing procedures are in place to guarantee product safety and quality.
  • BPL is prepared for a seamless changeover of plasma sources.

Conclusions:

  • The successful transition from UK to USA plasma requires stringent quality control and regulatory oversight.
  • BPL's proactive measures in plant cleaning and auditing are crucial for maintaining an uninterrupted supply of plasma-derived medicines.
  • This strategic shift underscores BPL's commitment to reliable pharmaceutical manufacturing.

Related Experiment Videos